ATE320486T1 - Isolierung von biologischen modulatoren aus bibiotheken mit biologisch vielfältigen genfragmenten - Google Patents

Isolierung von biologischen modulatoren aus bibiotheken mit biologisch vielfältigen genfragmenten

Info

Publication number
ATE320486T1
ATE320486T1 AT00922330T AT00922330T ATE320486T1 AT E320486 T1 ATE320486 T1 AT E320486T1 AT 00922330 T AT00922330 T AT 00922330T AT 00922330 T AT00922330 T AT 00922330T AT E320486 T1 ATE320486 T1 AT E320486T1
Authority
AT
Austria
Prior art keywords
libraries
isolation
activity
gene fragments
diverse gene
Prior art date
Application number
AT00922330T
Other languages
English (en)
Inventor
Paul Michael Watt
Wayne Robert Thomas
Original Assignee
Phylogica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phylogica Ltd filed Critical Phylogica Ltd
Application granted granted Critical
Publication of ATE320486T1 publication Critical patent/ATE320486T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ecology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00922330T 1999-05-05 2000-05-05 Isolierung von biologischen modulatoren aus bibiotheken mit biologisch vielfältigen genfragmenten ATE320486T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13271199P 1999-05-05 1999-05-05

Publications (1)

Publication Number Publication Date
ATE320486T1 true ATE320486T1 (de) 2006-04-15

Family

ID=22455261

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00922330T ATE320486T1 (de) 1999-05-05 2000-05-05 Isolierung von biologischen modulatoren aus bibiotheken mit biologisch vielfältigen genfragmenten
AT06003767T ATE469979T1 (de) 1999-05-05 2000-05-05 Isolierung von biologischen modulatoren aus bibliotheken mit biologisch vielvältigen genfragmenten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06003767T ATE469979T1 (de) 1999-05-05 2000-05-05 Isolierung von biologischen modulatoren aus bibliotheken mit biologisch vielvältigen genfragmenten

Country Status (10)

Country Link
US (7) US6994982B1 (de)
EP (4) EP2230303B1 (de)
AT (2) ATE320486T1 (de)
AU (6) AU771534B2 (de)
CA (2) CA2721199A1 (de)
DE (2) DE60044514D1 (de)
DK (1) DK2230303T3 (de)
ES (2) ES2402878T3 (de)
NZ (1) NZ515329A (de)
WO (1) WO2000068373A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803765B2 (en) 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
FR2824844B1 (fr) * 2001-05-18 2003-09-19 Genoway Procede de clonage par double selection et vecteurs pour ce procede
GB0126887D0 (en) * 2001-11-08 2002-01-02 Univ London Method for producing and identifying soluble protein domains
EP1451332B1 (de) * 2001-11-27 2008-02-13 neXyte AB Produktion eukaryontischer proteine und nukleinsäuremoleküle in c. elegans
US20050153304A1 (en) * 2003-04-10 2005-07-14 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Multivariate profiling of complex biological regulatory pathways
EP1754052B1 (de) * 2004-06-03 2015-07-22 Phylogica Limited Modulatoren biochemischer eigenschaften
US8575070B2 (en) 2006-02-20 2013-11-05 Phylogica Limited Methods of constructing and screening libraries of peptide structures
CA2663545A1 (en) 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof
FR2910493B1 (fr) * 2006-12-20 2012-12-14 Bio Modeling Systems Ou Bmsystems Procede de diversification aleatoire d'une sequence genetique permettant de preserver l'identite de certains segments internes de ladite sequence genetique
US8822409B2 (en) 2007-06-20 2014-09-02 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith
EP2812349B1 (de) 2012-02-10 2021-09-01 Cambridge Enterprise Limited Verfahren zur charakterisierung von wechselwirkungsbereichen bei zielproteinen
WO2014093417A1 (en) 2012-12-12 2014-06-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
WO2016105542A2 (en) 2014-12-24 2016-06-30 Neximmune, Inc Nanoparticle compositions and methods for immunotherapy
US10363299B2 (en) 2015-02-19 2019-07-30 University Of Virginia Patent Foundation Compositions and methods for preventing and treating rhinovirus infections
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
CN108883150A (zh) 2015-11-19 2018-11-23 阿斯克雷佩西治疗公司 具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
EP3426278B1 (de) 2016-03-07 2024-01-03 Vib Vzw Einzeldomänenantikörper gegen cd20
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3455245A2 (de) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutisches targeting von nichtzellulären strukturen
MX2019003895A (es) 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
EP3661536A4 (de) 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. Verfahren zur identifizierung und herstellung von pharmazeutischen wirkstoffen zur aktivierung eines tie2-rezeptors
WO2019075056A1 (en) 2017-10-10 2019-04-18 The Johns Hopkins University BIODEGRADABLE BIOMIMETIC PARTICLES
EP3743448A4 (de) 2018-01-26 2021-11-03 Orionis Biosciences, Inc. Xcr1-bindende wirkstoffe und verwendungen davon
KR102877915B1 (ko) 2018-02-05 2025-10-29 오리오니스 바이오사이언시즈 인코포레이티드 섬유아세포 결합제 및 이의 용도
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
JP2022520632A (ja) 2019-02-15 2022-03-31 インテグラル・モレキュラー・インコーポレイテッド 共通軽鎖を含む抗体及びその使用
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
EP4384219A4 (de) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. Zusammensetzungen, dosen und verfahren zur behandlung von schilddrüsenaugenkrankheit
JP2025523630A (ja) 2022-07-04 2025-07-23 ブイアイビー ブイゼットダブリュ 血液－脳脊髄液関門通過抗体
TW202430574A (zh) 2022-11-30 2024-08-01 美商積分分子股份有限公司 針對密連蛋白６之抗體，包括其雙特異性格式
EP4715008A2 (de) 2023-03-31 2026-03-25 Fritz Egger GmbH & Co. OG Kantenleiste, insbesondere doppelbodenkantenleiste
AU2024243709A1 (en) 2023-04-03 2025-11-06 Katholieke Universiteit Leuven Blood-brain barrier crossing antibodies
AU2024287547A1 (en) 2023-07-07 2026-01-22 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2225816T5 (es) 1990-02-01 2014-08-21 Siemens Healthcare Diagnostics Products Gmbh Producción y utilización de bancos de genes de anticuerpos humanos ("bibliotecas de anticuerpos humanos")
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
DE69333115D1 (de) 1992-09-22 2003-08-28 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
US5470953A (en) * 1993-12-23 1995-11-28 Icos Corporation Human β2 integrin α subunit
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5883074A (en) 1995-02-08 1999-03-16 Microcide Pharmaceuticals, Inc. Potentiators of antibacterial agents
EP0830457A1 (de) 1995-06-07 1998-03-25 Microcide Pharmaceuticals, Inc. Verfahren zur auffindung von antimikrobiellen zielen
US6238884B1 (en) * 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US20030215798A1 (en) * 1997-06-16 2003-11-20 Diversa Corporation High throughput fluorescence-based screening for novel enzymes
US5783431A (en) * 1996-04-24 1998-07-21 Chromaxome Corporation Methods for generating and screening novel metabolic pathways
US5763239A (en) 1996-06-18 1998-06-09 Diversa Corporation Production and use of normalized DNA libraries
US5955275A (en) * 1997-02-14 1999-09-21 Arcaris, Inc. Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
GB9703406D0 (en) 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
US5843698A (en) * 1997-04-30 1998-12-01 Universal Ventures Deleteriously affecting members of a target species by exposure to a component of symbiont or food source of an adjoiner species that is symbiotic with the target species
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6583275B1 (en) * 1997-07-02 2003-06-24 Genome Therapeutics Corporation Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics
EP1053347B1 (de) 1998-01-09 2007-02-28 Phylogica Limited Nachweisverfahren für peptide
CA2319828A1 (en) * 1998-01-29 1999-08-05 Miller, Samuel High density arrays for proteome analysis and methods and compositions therefor
US6316223B1 (en) 1998-03-30 2001-11-13 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system
US6190908B1 (en) 1998-08-12 2001-02-20 The Scripps Research Institute Modulation of polypeptide display on modified filamentous phage
US6287825B1 (en) * 1998-09-18 2001-09-11 Molecular Staging Inc. Methods for reducing the complexity of DNA sequences
US6720139B1 (en) * 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
US6074815A (en) * 1999-03-08 2000-06-13 Universal Ventures Selection of test species for testing to identify components thereof that deleteriously affect a target species member
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US6150127A (en) * 1999-11-30 2000-11-21 Universal Ventures Causing a desirable change in a behavior pattern
EP2213743A1 (de) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albuminfusionsproteine
JP2004503038A (ja) 2000-07-12 2004-01-29 カリフォルニア・インスティテュート・オブ・テクノロジー 一次タンパク質配列から三次元タンパク質構造を決定する方法

Also Published As

Publication number Publication date
AU4275900A (en) 2000-11-21
AU771534B2 (en) 2004-03-25
AU2003302489B2 (en) 2008-03-06
AU2003302489B8 (en) 2008-05-08
EP1696038A2 (de) 2006-08-30
EP2230303B1 (de) 2013-01-16
AU2011200020A1 (en) 2011-01-27
EP1179059B1 (de) 2006-03-15
US20080139401A1 (en) 2008-06-12
US6994982B1 (en) 2006-02-07
AU2006200082A1 (en) 2006-02-09
CA2372464A1 (en) 2000-11-16
DK2230303T3 (da) 2013-04-15
ES2260009T3 (es) 2006-11-01
EP1696038A3 (de) 2007-02-14
AU2009251209A1 (en) 2010-01-28
CA2372464C (en) 2012-07-31
AU2006200082B2 (en) 2007-12-13
EP1696037A3 (de) 2007-01-24
CA2721199A1 (en) 2000-11-16
EP1696038B1 (de) 2010-06-02
US20120214709A1 (en) 2012-08-23
DE60026695T2 (de) 2006-11-02
ES2402878T3 (es) 2013-05-10
AU2003302489A1 (en) 2004-09-09
US20100227777A1 (en) 2010-09-09
US20050287580A1 (en) 2005-12-29
DE60044514D1 (de) 2010-07-15
EP2230303A1 (de) 2010-09-22
ATE469979T1 (de) 2010-06-15
EP1696037A2 (de) 2006-08-30
US20110092386A1 (en) 2011-04-21
EP1179059A1 (de) 2002-02-13
AU2009251209B2 (en) 2012-10-11
AU2008200790A1 (en) 2008-03-13
WO2000068373A1 (en) 2000-11-16
NZ515329A (en) 2004-05-28
US20150344875A1 (en) 2015-12-03
EP1179059A4 (de) 2003-01-22
DE60026695D1 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
DE60026695D1 (de) ISOLIERUNG VON BIOLOGISCHEN MODULATOREN AUS BIBIOTHEKEN MIT BIOLOGISCH VIELFäLTIGEN GENFRAGMENTEN
NO883592L (no) Enzym.
ATE313625T1 (de) ßFUNCTIONAL GENOMICSß UNTER VERWENDUNG VON ZINK FINGER PROTEINEN
ATE551352T1 (de) Peptidakzeptorbindungsverfahren
DE68928467D1 (de) RNS-Katalysator zur Spaltung von spezifischen RNS-Sequenzen
DE69932813D1 (de) Nukleinsäurebindungsproteine
ATE492644T1 (de) Transfer von mrna unter verwendung von polykationischen verbindungen
DE60213803D1 (en) Happier mapping
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
EP1365025A4 (de) Agarase und gen dafür
ATE188739T1 (de) Klonierung hühner-anaemia-virus-dna
EE200100040A (et) Meetod raku fenotüüpi muutva modulaatori identifitseerimiseks ja valmistamiseks, sihtmärkbiomolekulide eraldamiseks ja/või samastamiseks ning meditsiinitoote arendamiseks ja valmistamiseks
AU2002368411A1 (en) Method for immobilizing biologic molecules on solid surfaces
WO2002048401A3 (en) Nested oligonucleotides containing hairpin for nucleic acid amplification
DE50210818D1 (de) Verfahren zur genexpression
MX9703475A (es) D-pantolactona hidrolasa y gen que codifica para la misma.
DE60329594D1 (de) Methode zur Herstellung eines Polypeptides, einer RNA oder einer anderen Verbindung in Tumorgewebe
DE59901930D1 (de) Expressionssystem zur produktion von proteinen
DK1180138T3 (da) Polynukleotidmotor, motorsystem, fremstilling og anvendelse deraf
DK1123396T3 (da) Minimale promotorer og anvendelser deraf
PT983366E (pt) Adn que codifica uma sintetase de quitina de artropode
ATE213268T1 (de) Fanconi-gen ii
YU4101A (sh) Novi postupci za identifikovanje liganada i ciljnih biomolekula

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1179059

Country of ref document: EP